Wall Street Thinks This Biotech Stock Can Soar 45%. Here's Why Analysts Are Right.

Alnylam Pharmaceuticals (ALNY) carries a consensus price target of $436 from Wall Street analysts, implying 45% upside from current levels. Of the 29 analysts covering the stock, 21 rate it buy or strong buy, according to data cited by The Motley Fool.

The bullish thesis centers on Alnylam's commercial transformation. First-quarter product revenue hit $1.04 billion, up 121% year-over-year, powered by its ATTR amyloidosis franchise. The company is moving beyond rare disease into larger addressable markets including cardiomyopathy and hypertension, leveraging its RNA interference delivery platform as a competitive advantage.

The valuation presents a headwind. Alnylam trades at 75 times trailing earnings, a premium multiple that leaves little room for execution missteps. Competitive pricing pressure in the RNAi space adds risk to margin assumptions embedded in analyst models.

The 121% revenue growth rate signals strong commercial traction, but the question is whether pipeline expansion into mainstream indications can justify the current multiple as the rare-disease tailwinds mature.